Know Cancer

or
forgot password

A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.


N/A
N/A
5 Months
Open (Enrolling)
Both
Hemangioma

Thank you

Trial Information

A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.


Serum and urine will be collected from children with hemangiomas and age matched healthy
controls at 2,4,6,9,12,18 and 24 months of age. Children with hemangiomas will also have
ultrasound examination performed at each visit.


Inclusion Criteria:



- Children with hemangioma

- Age ≤ 5 months.

- Doppler ultrasound confirmed diagnosis of hemangioma to rule out presence of vascular
malformation.

- Age matched control ≤ 5 months (no hemangioma)

Exclusion Criteria:

- Hemangioma treated prior to or during study period with laser, steroids, interferon,
or propanolol, or any other drug or device intended to inhibit the growth of the
hemangioma.

- Known history of sickle cell anemia, thalassemia, or other hemoglobinopathy.

- Hemangioma presented as fully formed at birth consistent with rapidly involuting or
non-involuting congenital hemangioma.

- PHACES syndrome- posterior fossa malformations, hemangioma, arterial anomalies,
cardiac anomalies, eye abnormalities, sternal anomalies.

- Parent/guardian unable to speak english to provide informed consent and no
interpreter is present.

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Gayle M Gordillo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University

Authority:

United States: Institutional Review Board

Study ID:

10-00482

NCT ID:

NCT01598116

Start Date:

December 2010

Completion Date:

December 2015

Related Keywords:

  • Hemangioma
  • Hemangioma

Name

Location

Nationwide Children's HospitalColumbus, Ohio  43205-2696